Pharmacoeconomic evaluation of eligard® and other LHRH analogues as androgen deprivation therapy for advanced and metastatic prostate cancer | Avaliação farmacoeconômica de diferentes apresentações de eligard® e outros análogos LHRH para supressão androgênica em pacientes com câncer de próstata avançado ou metastático

Journal article published in 2014 by A. D. Sasse , A. C. De Carvalho, R. R. Munhoz

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload